本帖最后由 老马 于 2013-3-13 13:43 编辑 , J6 X& E* T9 H; c7 y4 d
, Q6 r) Q6 _( A
健择（吉西他滨）+顺铂+阿瓦斯汀& r( ^+ H3 ?/ `6 k% `
Gemzar +Cisplatin + Avastin
4 j! G. D$ `- u5 G9 ~6 mhttp://annonc.oxfordjournals.org/content/21/9/1804.full
' U; ~, Y* k1 ?5 y0 Z: {Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
. X( J6 O$ c. h- X F0 EPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
+ ], G2 w+ C9 x! ~; _) FResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. : E( c1 V9 O8 [4 g& B. f
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 820)
9 n; L/ l: @2 E3 W! }( f
华为网盘附件：
) d. \2 b+ f" z) ]3 w* h4 N4 ]【华为网盘】ava.JPG
7 W# _7 b7 N3 J8 i! c' z- i |
显身卡
